Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study

the RAINBOW Investigators

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study'. Together they form a unique fingerprint.

Medicine & Life Sciences